Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02184572 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
A Phase 3 study of Measles-Mumps-Rubella Vaccine and Measles; Mumps; Rubella, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,742
- Enrollment target
- 20
- Study locations
NCT02184572 is a Phase 3 study of Measles-Mumps-Rubella Vaccine and Measles; Mumps; Rubella that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,742 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT02184572, a Phase 3 study of Measles-Mumps-Rubella Vaccine and Measles; Mumps; Rubella, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,742 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.
Conditions Studied
Interventions
- BIOLOGICAL Priorix
- BIOLOGICAL M-M-R II
- BIOLOGICAL Varivax
- BIOLOGICAL Havrix
- BIOLOGICAL Prevnar 13
Study Locations (20)
California
- GSK Investigational Site - Anaheim
- GSK Investigational Site - Baldwin Park
- GSK Investigational Site - Daly City
- GSK Investigational Site - Fresno
- GSK Investigational Site - Hayward
- GSK Investigational Site - Oakland
- GSK Investigational Site - Paramount
- GSK Investigational Site - Pleasanton
- GSK Investigational Site - Roseville
- GSK Investigational Site - Sacramento
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Jose
- GSK Investigational Site - Santa Clara
- GSK Investigational Site - Walnut Creek
Arkansas
- GSK Investigational Site - Fayetteville
- GSK Investigational Site - Jonesboro
Alabama
- GSK Investigational Site - Birmingham
Arizona
- GSK Investigational Site - Tucson
Colorado
- GSK Investigational Site - Colorado Springs
Connecticut
- GSK Investigational Site - Norwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,742 participants |
| Start Date | 2014-08-25 |
| Est. Completion | 2015-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02184572
The ClinicalTrials.gov registry entry for NCT02184572 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,742 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Measles-Mumps-Rubella Vaccine appearing as the primary indexed condition, and to 5 interventions - of which Priorix is the first listed.
NCT02184572 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT02184572 about?
NCT02184572 is a clinical study titled "Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age". The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.
What is the current status of trial NCT02184572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,742 participants. The study started on 2014-08-25. Estimated completion is 2015-12-22.
What conditions does trial NCT02184572 study?
This clinical trial studies the following conditions: Measles-Mumps-Rubella Vaccine, Measles; Mumps; Rubella.
What interventions are being tested in trial NCT02184572?
The interventions under investigation include: Priorix (BIOLOGICAL), M-M-R II (BIOLOGICAL), Varivax (BIOLOGICAL), Havrix (BIOLOGICAL), Prevnar 13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02184572?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02184572 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Measles-Mumps-Rubella Vaccine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.